Tilia Fiduciary Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-101
Closed -$5K 525
2022
Q1
$5K Buy
+101
New +$4.82K ﹤0.01% 449

Other funds holding ARKG

Tilia Fiduciary Partners's ARKG Position: Q2 2022 in Review

Tilia Fiduciary Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 101 shares — an estimated $5K sold.

Tilia Fiduciary Partners first reported a position in ARKG in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 334 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

  • Tilia Fiduciary Partners reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
  • Tilia Fiduciary Partners sold 101 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $5K.
  • Tilia Fiduciary Partners first reported a position in ARK Genomic Revolution ETF in Q1 2022 and held it in 1 quarter.
  • Tilia Fiduciary Partners's ARK Genomic Revolution ETF position peaked at $5K in Q1 2022.
  • 334 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Tilia Fiduciary Partners's 13F filing for Q2 2022, filed 1 Aug 2022.